ATE506615T1 - Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten - Google Patents

Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten

Info

Publication number
ATE506615T1
ATE506615T1 AT00992018T AT00992018T ATE506615T1 AT E506615 T1 ATE506615 T1 AT E506615T1 AT 00992018 T AT00992018 T AT 00992018T AT 00992018 T AT00992018 T AT 00992018T AT E506615 T1 ATE506615 T1 AT E506615T1
Authority
AT
Austria
Prior art keywords
methods
reagents
diagnosis
imaging
treatment
Prior art date
Application number
AT00992018T
Other languages
English (en)
Inventor
Joseph Witztum
Sotirios Tsimikas
Wulf Palinski
Peter Shaw
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE506615T1 publication Critical patent/ATE506615T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
AT00992018T 1999-10-26 2000-10-26 Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten ATE506615T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16149399P 1999-10-26 1999-10-26
PCT/US2000/041651 WO2001032070A2 (en) 1999-10-26 2000-10-26 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease

Publications (1)

Publication Number Publication Date
ATE506615T1 true ATE506615T1 (de) 2011-05-15

Family

ID=22581404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00992018T ATE506615T1 (de) 1999-10-26 2000-10-26 Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten

Country Status (9)

Country Link
EP (1) EP1224461B1 (de)
JP (1) JP2003513027A (de)
AT (1) ATE506615T1 (de)
AU (1) AU773370B2 (de)
CA (1) CA2389849A1 (de)
DE (1) DE60045869D1 (de)
MX (1) MXPA02004244A (de)
NZ (1) NZ531712A (de)
WO (1) WO2001032070A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
JP2005502618A (ja) 2001-06-04 2005-01-27 ザ・ジェネラル・ホスピタル・コーポレイション 光力学的化合物を用いて脆弱なプラークを検出および治療する方法
MXPA04002848A (es) 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
JP2003279571A (ja) * 2002-03-20 2003-10-02 Kyowa Hakko Kogyo Co Ltd 炎症性疾患検出方法、検出薬、およびその予防治療薬探索方法
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0202959D0 (sv) * 2002-10-04 2002-10-04 Forskarpatent I Syd Ab Ideon Peptide-Base passive immunization therapy for treatment of atherosclerosis
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
JP2007531537A (ja) 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
CN103908669B (zh) * 2004-04-15 2017-07-04 阿瑟拉生物技术公司 磷酸胆碱偶联物和相应抗体
CA2602946A1 (en) * 2005-03-22 2006-09-28 Medstar Health, Inc. Delivery systems and methods for diagnosing and treating cardiovascular diseases
WO2011098407A1 (en) * 2010-02-12 2011-08-18 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Microspheres
WO2011134060A1 (en) * 2010-04-27 2011-11-03 National Research Council Of Canada Anti-icam-1 single domain antibody and uses thereof
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
MX364425B (es) 2011-08-09 2019-04-25 Athera Biotechnologies Ab Star Nuevos anticuerpos contra fosforilcolina.
EP2741770A4 (de) 2011-08-09 2014-12-31 Athera Biotechnologies Ab Antikörperbindung an phosphorylcholin (pc) und/oder pc-konjugate
CN120093699B (zh) * 2025-03-06 2025-11-14 浙江大学 用于定位并稳定动脉粥样硬化斑块的诊疗分子、纳米粒及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021581A1 (en) * 1996-11-08 1998-05-22 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) * 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
AU2001259730A1 (en) * 2000-05-12 2001-11-26 The Regents Of The University Of California Standardized oxidized ldl assay

Also Published As

Publication number Publication date
AU3790801A (en) 2001-05-14
EP1224461A4 (de) 2003-06-25
WO2001032070A3 (en) 2001-10-04
EP1224461A2 (de) 2002-07-24
JP2003513027A (ja) 2003-04-08
MXPA02004244A (es) 2002-11-04
CA2389849A1 (en) 2001-05-10
DE60045869D1 (de) 2011-06-01
WO2001032070A2 (en) 2001-05-10
AU773370B2 (en) 2004-05-20
EP1224461B1 (de) 2011-04-20
NZ531712A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
DE60045869D1 (de) Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
EP1578923A4 (de) Lösliche mic-polypeptide als marker zur diagnose, prognose und behandlung von krebs sowie autoimmunkrankheiten oder -erkrankungen
ATE223051T1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
BRPI0619748B8 (pt) anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste
DE69922261D1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
RU2178711C1 (ru) Способ прогнозирования заболеваний копытец у коров после отела
ATE321570T1 (de) Verfahren zur behandlung von hämostatischen störungen durch lösliches p-selectin
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
Şirli et al. Comparison between the M and XL probes for liver fibrosis assessment by transient elastography
EP1977234A4 (de) Moleküle zur behandlung von lungenerkrankungen mit einer immunreaktion mit verbindungsgewebe in der lunge
Olsen et al. Indirect immunofluorescence microscopy of lichen planus
US12186411B2 (en) Labeled probe and methods of use
EA200300507A1 (ru) Радиофармацевтические агенты для диагностики болезни альцгеймера
DE50103907D1 (de) Verwendungen der Aldose-1-Epimerase (Mutarotase) für die Diagnose von Entzündungserkrankungen und Sepsis
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
US7465434B2 (en) Diagnosis of blood clots using fibrin-binding proteins bound with contrast agents
Naredo et al. Doppler techniques
Eckrich et al. In vivo analysis of noise dependent activation of white blood cells and microvascular dysfunction in mice
Seidenari et al. Pre‐treatment of nickel test areas with sodium lauryl sulfate detects nickel sensitivity in subjects reacting negatively to routinely performed patch tests
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
EP0981357A4 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von neuropsychiatrischen erkrankungen
Campbell et al. The clinical effectiveness of hand held Doppler examination for diagnosis of reflux in patients with varicose veins
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
DE60127935D1 (de) Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie
Chen et al. Doppler ultrasound imaging and shear wave elastography for evaluation of interstitial fibrosis/tubular atrophy in IgA nephropathy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties